June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Faricimab causes rapid and sustained intraocular suppression of Ang-2 and VEGF-A for up to 16 weeks in nAMD and DME
Author Affiliations & Notes
  • KATRIJN BOGMAN
    F. Hoffmann-La Roche Limited, Basel, Switzerland
  • Robert Avery
    California Retina Consultants, California, United States
  • Ivo Stoilov
    Genentech Inc, South San Francisco, California, United States
  • Cheikh Diack
    F. Hoffmann-La Roche Limited, Basel, Switzerland
  • Footnotes
    Commercial Relationships   KATRIJN BOGMAN F. Hoffmann-La Roche. Ltd., Code E (Employment); Robert Avery Adverum, Alcon, Alimera, Allergan, Amgen, Apellis, AsclepiX, Bausch + Lomb, Cardinal, Clearside Biomedical, Coherus, EyePoint, Genentech, Inc., Helio Vision, InFocus Capital Partners, Notal Vision, Novartis, NVasc, Ocular Therapeutix, Outlook, Pr3vent, Regenxbio, Replenish, Re-Vana, Santen, Tenpoint Therapeutics, Vial, Visionary Ventures; Stock: Adverum, Alcon, Aldeyra, EyePoint, InFocus Capital Partners, Iveric Bio, Kodiak Sciences, Novartis, NVasc, Outlook, Regeneron, Replenish, Re-Vana, Verana Health, Visionary Ventures, Code C (Consultant/Contractor); Ivo Stoilov Genentech, Inc., Code E (Employment); Cheikh Diack F. Hoffmann-La Roche. Ltd., Code E (Employment)
  • Footnotes
    Support  F. Hoffmann-La Roche Ltd. (Basel, Switzerland) provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation. Third- party writing assistance was provided by Neil Norcross, PhD, and Luke Carey, PhD, CMPP, of Envision Pharma Group and funded by F.Hoffmann-La Roche Ltd.
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2633. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      KATRIJN BOGMAN, Robert Avery, Ivo Stoilov, Cheikh Diack; Faricimab causes rapid and sustained intraocular suppression of Ang-2 and VEGF-A for up to 16 weeks in nAMD and DME. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2633.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Faricimab is a bispecific antibody designed to inhibit angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), promote vascular stability, and improve outcomes in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The purpose of this analysis was to evaluate the intraocular pharmacodynamics of faricimab.

Methods : Optional aqueous humor (AH) samples were collected from patients in randomized, double-masked, active comparator–controlled, phase 2/3 trials in nAMD (AVENUE [NCT02484690], STAIRWAY [NCT03038880], TENAYA [NCT03823287], and LUCERNE [NCT03823300]) and DME (BOULEVARD [NCT02699450], YOSEMITE [NCT03622580], and RHINE [NCT03622593]). Free Ang-2 and VEGF-A levels were measured using validated assays. A population pharmacokinetic/pharmacodynamic model (popPKPD) was developed using phase 2/3 pooled data, including AH data from ~300 patients, corresponding to 1025 free Ang-2 concentrations, 1345 free VEGF-A concentrations, and 1095 faricimab concentrations. Only patients with at least 1 non–below the limit of quantification (BLQ) sample were included in the popPKPD analysis.

Results : Mean baseline VEGF-A levels were 135 pg/mL and 58 pg/mL in patients with DME and nAMD, respectively. Mean baseline Ang-2 levels were 13.4 pg/mL and 8.1 pg/mL in patients with DME and nAMD, respectively. Approximately 75% of post dose Ang-2 observations were BLQ. The popPKPD model described the observed data well. The model derived Ang-2 and VEGF-A concentration-time profiles showed that following intravitreal injection of faricimab, AH concentrations of Ang-2 and VEGF-A were rapidly suppressed to nearly unquantifiable levels. At 8 weeks post dose, median Ang-2 concentrations remained suppressed by ~80%. At 16 weeks post dose, median VEGF-A concentrations returned to baseline, but median Ang-2 levels remained below baseline.

Conclusions : PopPKPD analyses showed that faricimab treatment leads to rapid and sustained suppression of AH Ang-2 and VEGF-A levels, with Ang-2 suppression through 16 weeks post dose, supporting the extended durability demonstrated in phase 3 trials.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×